SARS-CoV-2 Orf9b suppresses type I interferon responses by targeting TOM70
Open accessAbstract
COVID-19 is caused by SARS-CoV-2. 1 As of July 16th, 2020, there were 13,579,581 diagnosed cases and 584,782 deaths attributed to COVID-19 reported globally ( https://coronavirus.jhu.edu/map.html ). 2 Unfortunately, there is still no effective drug or vaccine for treating this disease. To accelerate drug development, there is an urgent need to identify critical molecular targets and the role they play in infection. Herein, we reported that Orf9b localizes on the membrane of mitochondria and suppresses type I interferon (IFN-I) responses through association with TOM70, and TOM70 overexpression could largely rescue this inhibition. Our results suggest the potential of targeting Orf9b-TOM70 interaction as a novel therapeutic strategy of COVID-19.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The Alpha variant contains non-spike mutations including nsp6:Δ106-108 and nucleocapsid mutations D3L, R203K and G204R, which may increase transmission by antagonizing innate immunity.
“The Alpha variant also contains several non-spike mutations including nsp6:Δ106-108 and the nucleocapsid mutations D3L, R203K and G204R, which may increase transmission by antagonizing innate immunity 25,[185][186][187] .”
From The biological and clinical significance of emerging SARS-CoV-2 variants (2021) · cites this paper as [186]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
A new coronavirus associated with human respiratory disease in China
Wu, F., Zhao, S., Yu, B., Chen, Y.-M., Wang, W., Song, Z.-G., Hu, Y., Tao, Z.-W., Tian, J.-H., Pei, Y.-Y., et al. (2020) · Nature · doi:10.1038/s41586-020-2008-3 · Cited by 11,688 · see citing works
An interactive web-based dashboard to track COVID-19 in real time
Dong, E., Du, H., & Gardner, L. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30120-1 · Cited by 10,048 · see citing works
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing
Gordon, D. E., Jang, G. M., Bouhaddou, M., Xu, J., Obernier, K., White, K. M., O’Meara, M. J., Rezelj, V. V., Guo, J. Z., Swaney, D. L., et al. (2020) · Nature · doi:10.1038/s41586-020-2286-9 · Cited by 4,405 · see citing works
Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19
Blanco-Melo, D., Nilsson-Payant, B. E., Liu, W.-C., Uhl, S., Hoagland, D., Møller, R., Jordan, T. X., Oishi, K., Panis, M., Sachs, D., et al. (2020) · Cell · doi:10.1016/j.cell.2020.04.026 · Cited by 4,222 · see citing works
SARS-CoV-2 productively infects human gut enterocytes
Lamers, M. M., Beumer, J., van der Vaart, J., Knoops, K., Puschhof, J., Breugem, T. I., Ravelli, R. B. G., Paul van Schayck, J., Mykytyn, A. Z., Duimel, H. Q., et al. (2020) · Science · doi:10.1126/science.abc1669 · Cited by 1,573 · see citing works
Type I Interferons in Host Defense
Stetson, D. B., & Medzhitov, R. M. (2006) · Immunity · doi:10.1016/j.immuni.2006.08.007 · Cited by 1,194 · see citing works
Lactate Is a Natural Suppressor of RLR Signaling by Targeting MAVS
Zhang, W., Wang, G., Xu, Z., Tu, H.-Q., Hu, F., Dai, J., Chang, Y., Chen, Y., Lu, Y., Zeng, H., et al. (2019) · Cell · doi:10.1016/j.cell.2019.05.003 · Cited by 598 · see citing works
Shi, C.-S., Qi, H.-Y., Boularan, C., Huang, N., Abu-Asab, M. S., Shelhamer, J. H., & Kehrl, J. H. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1303196 · Cited by 469 · see citing works
Self-citationAntiviral Signaling Through Pattern Recognition Receptors
Kawai, T., & Akira, S. (2006) · The Journal of Biochemistry · doi:10.1093/jb/mvm032 · Cited by 452 · see citing works
SARS-CoV-2 proteome microarray for global profiling of COVID-19 specific IgG and IgM responses
Jiang, H.-W., Li, Y., Zhang, H.-N., Wang, W., Yang, X., Qi, H., Li, H., Men, D., Zhou, J., & Tao, S.-C. (2020) · Nature Communications · doi:10.1038/s41467-020-17488-8 · Cited by 329 · see citing works
Self-citationTom70 mediates activation of interferon regulatory factor 3 on mitochondria
Liu, X.-Y., Wei, B., Shi, H.-X., Shan, Y.-F., & Wang, C. (2010) · Cell Research · doi:10.1038/cr.2010.103 · Cited by 171 · see citing works
TOM70 Sustains Cell Bioenergetics by Promoting IP3R3-Mediated ER to Mitochondria Ca2+ Transfer
Filadi, R., Leal, N. S., Schreiner, B., Rossi, A., Dentoni, G., Pinho, C. M., Wiehager, B., Cieri, D., Calí, T., Pizzo, P., et al. (2018) · Current Biology · doi:10.1016/j.cub.2017.12.047 · Cited by 158 · see citing works
SARS corona virus peptides recognized by antibodies in the sera of convalescent cases
Guo, J. P., Petric, M., Campbell, W. J., & McGeer, P. L. (2004) · Virology · doi:10.1016/j.virol.2004.04.017 · Cited by 137 · see citing works
Chan, N., Likić, V., Waller, R. F., Mulhern, T., & Lithgow, T. (2006) · Journal of Molecular Biology · doi:10.1016/j.jmb.2006.02.062 · Cited by 107 · see citing works
Wei, X., Du, M., Xie, J., et al. (2020) · Journal of Human Genetics · doi:10.1038/s10038-019-0714-1 · Cited by 35 · see citing works
Self-citationZhu, J., Deng, Y., Wang, X., Li, X.-F., Zhang, N., Liu, Z., Zhang, B., Qin, C., & Xie, Z. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.05.02.074021 · Cited by 26 · see citing works
Self-citation
Flagged first, then by citations
Research works printed but not linked: 1
- Stukalov, A.et al. Multi-level proteomics reveals host-perturbation strategies of SARS-CoV-2 and SARS-CoV. https://www.biorxiv.org/content/10.1101/ 2020.06.17.156455v1 (2020). · DOI
Cited by
Sorted by citations
The biological and clinical significance of emerging SARS-CoV-2 variants
Tao, K., Tzou, P. L., Nouhin, J., Gupta, R. K., de Oliveira, T., Kosakovsky Pond, S. L., Fera, D., & Shafer, R. W. (2021) · Nature Reviews Genetics · doi:10.1038/s41576-021-00408-x · Cited by 1,009 · see citing works
A critical overview of computational approaches employed for COVID-19 drug discovery
Muratov, E. N., Amaro, R., Andrade, C. H., Brown, N., Ekins, S., Fourches, D., Isayev, O., Kozakov, D., Medina-Franco, J. L., Merz, K. M., et al. (2021) · Chemical Society Reviews · doi:10.1039/d0cs01065k · Cited by 206 · see citing works
Evolution of enhanced innate immune evasion by the SARS-CoV-2 B.1.1.7 UK variant
Thorne, L. G., Bouhaddou, M., Reuschl, A.-K., Zuliani-Alvarez, L., Polacco, B., Pelin, A., Batra, J., Whelan, M. V. X., Ummadi, M., Rojc, A., et al. (2021) · doi:10.1101/2021.06.06.446826 · Cited by 91 · see citing works
Host mitochondrial transcriptome response to SARS-CoV-2 in multiple cell models and clinical samples
Miller, B., Silverstein, A., Flores, M., Cao, K., Kumagai, H., Mehta, H. H., Yen, K., Kim, S. J., & Cohen, P. (2021) · Scientific Reports · doi:10.1038/s41598-020-79552-z · Cited by 86 · see citing works
Attenuation of SARS-CoV-2 infection by losartan in human kidney organoids
Rahmani, W., Chung, H., Sinha, S., Bui-Marinos, M. P., Arora, R., Jaffer, A., Corcoran, J. A., Biernaskie, J., & Chun, J. (2022) · iScience · doi:10.1016/j.isci.2022.103818 · Cited by 25 · see citing works
- Authors
- Jiang, H.-W., Zhang, H.-N., Meng, Q.-F., Xie, J., Li, Y., Chen, H., Zheng, Y.-X., Wang, X.-N., Qi, H., Zhang, J., Wang, P.-H., Han, Z.-G., & Tao, S.-C.
- Affiliations
- Shanghai Jiao Tong University (CN)
- Shandong University (CN)
- Corresponding author
- Tao, Sheng-ce
- ORCID
- Venue
- Cellular & Molecular Immunology
- Published
- 2020-07-29
- Volume
- 17
- Issue
- 9
- Pages
- 998-1000
- ISSN
- 1672-7681 (ISSN-L)
- 2042-0226
- PMC
- PMC7387808
- OpenAlex
- W3045756756
- Cited by
- 351
- References
- 16
- Citations by year
- 2026: 18 · 2025: 34 · 2024: 40 · 2023: 57 · 2022: 81 · 2021: 106 · 2020: 15
- FWCI
- 22.73
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Cellular and Molecular Immunology (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China (31670831, 31970130, 31900112, 21907065)
- National Key Research and Development Program of China Grant
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › interferon and immune responses
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Keywords
- SARS-CoV-2, ORF9b, Tom70, type I interferon, interferon inhibition, mitochondrial membrane, COVID-19 pandemic, antiviral drug targets, host-virus interaction
- MeSH terms
- Betacoronavirus, SARS-CoV-2, Mitochondrial Precursor Protein Import Complex Proteins, Amino Acid Sequence, Gene Expression Regulation, Humans, Mitochondria, Promoter Regions, Genetic, Protein Binding, Viral Proteins, Signal Transduction, Open Reading Frames, Sequence Alignment, Interferon-beta, Sequence Homology, Amino Acid, Mitochondrial Membrane Transport Proteins, Severe acute respiratory syndrome-related coronavirus, Host-Pathogen Interactions, HEK293 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
